Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C et al
- PMID: 33692020
- DOI: 10.1136/annrheumdis-2021-220166
Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C et al
Keywords: COVID-19; biological therapy; rituximab.
Conflict of interest statement
Competing interests: JAS reports research support from Amgen and Bristol-Myers Squibb and consultancy fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, Optum, and Pfizer. ZSW reports research support from Bristol-Myers Squibb and Principia and consulting fees from Viela Bio and MedPace.
Comment on
-
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.Ann Rheum Dis. 2021 Jun;80(6):817-819. doi: 10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12. Ann Rheum Dis. 2021. PMID: 33436385 Free PMC article. No abstract available.
-
Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'.Ann Rheum Dis. 2023 Jun;82(6):e130. doi: 10.1136/annrheumdis-2021-220148. Epub 2021 Mar 10. Ann Rheum Dis. 2023. PMID: 33692021 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
